Ownership and insider activity for Skye Bioscience, Inc. (SKYE): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc.
Price
| Price | $1.70 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-18 | Schwab Andrew J. | S-Sale | 253,080 | $96K |
| 2026-08-19 | Schwab Andrew J. | S-Sale | 57,476 | $20K |
| 2026-08-20 | Schwab Andrew J. | S-Sale | 6,495 | $2K |
| 2026-08-18 | Schwab Andrew J. | S-Sale | 45,090 | $17K |
| 2026-08-19 | Schwab Andrew J. | S-Sale | 10,255 | $4K |
| 2026-08-20 | Schwab Andrew J. | S-Sale | 1,159 | $371 |
| 2026-08-18 | Schwab Andrew J. | S-Sale | 1,830 | $695 |
| 2026-08-19 | Schwab Andrew J. | S-Sale | 409 | $143 |
| 2026-08-20 | Schwab Andrew J. | S-Sale | 46 | $15 |
| 2026-08-18 | 5AM Partners VII, LLC | S-Sale | 253,080 | $96K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $64820 | $259955 | $1.9M | $1.8M | $2.5M | $9.0M | $1.2M | $1.3M | $68.4M | $5.9M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $19.9M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | $74121 | $158242 | $5065 | $10474 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $279489 | $555811 | $2.0M | $2.0M | $2.7M | $9.6M | $8.9M | $11.7M | $70.8M | $27.1M |
| Property, Plant & Equipment | $9584 | $1407 | $3445 | $1983 | $7341 | $234682 | $159045 | $281259 | $1.9M | $1.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $323363 | $557218 | $2.0M | $2.0M | $2.7M | $9.9M | $9.1M | $11.9M | $72.8M | $28.3M |
| Accounts Payable | $274650 | $100921 | $15597 | $139809 | $381372 | $900010 | $1.8M | $956754 | $569252 | $2.0M |
| Short-term Debt | 0 | $235000 | 0 | 0 | $64062 | $2.0M | $1.9M | $4.4M | 0 | 0 |
| Total Current Liabilities | $661958 | $805974 | $15.9M | $970818 | $787199 | $3.9M | $12.1M | $13.9M | $4.3M | $8.2M |
| Long-term Debt | 0 | 0 | $1.4M | $387070 | $1.4M | 0 | 0 | 0 | 0 | $83999 |
| Total Liabilities | $1.8M | $1.4M | $17.5M | $1.4M | $2.2M | $4.0M | $12.1M | $14.1M | $4.6M | $8.3M |
| Retained Earnings | -$10.9M | -$14.0M | -$33.2M | -$32.2M | -$38.7M | -$47.3M | -$66.7M | -$104.4M | -$130.9M | -$186.9M |
| Total Equity | -$1.5M | -$800078 | -$15.6M | $548058 | $450786 | $5.9M | -$3.0M | -$2.1M | $68.2M | $20.0M |
| Total Debt | 0 | $235000 | $1.4M | $387070 | $1.5M | $2.1M | $2.0M | $4.6M | $455590 | $273646 |
| Net Debt | -$64820 | -$24955 | -$492413 | -$1.4M | -$971607 | -$6.8M | $737999 | $3.4M | -$68.0M | -$25.5M |
| Working Capital | -$382469 | -$250163 | -$14.0M | $1.0M | $1.9M | $5.7M | -$3.2M | -$2.3M | $66.5M | $18.9M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 3.30 |
Profitability
| Return on Equity | -279.29% |
| Return on Invested Capital | -286.55% |
| Return on Assets | -197.52% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALGS · BRNS · CVM · INMB · KZR · LVTX · MRSN
Explore sector: Healthcare · Biotechnology
More sections of SKYE: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks